应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
CAMP Camp4 Therapeutics Corp.
休市中 12-20 15:59:59 EST
5.20
-0.14
-2.62%
盘后
5.20
+0.00
0.00%
16:20 EST
最高
6.30
最低
4.66
成交量
98.43万
今开
5.53
昨收
5.34
日振幅
30.71%
总市值
1.05亿
流通市值
3,546万
总股本
2,016万
成交额
515.71万
换手率
14.43%
流通股本
682.00万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
资讯
新帖
简况
单月超6亿美元,医药企业IPO规模重返疫情前水平
财通社 · 11-25
单月超6亿美元,医药企业IPO规模重返疫情前水平
Camp4 Therapeutics Corporation2024财年第三财季实现净利润-13.48百万美元,同比减少15.21%
市场透视 · 11-25
Camp4 Therapeutics Corporation2024财年第三财季实现净利润-13.48百万美元,同比减少15.21%
美国研究综述-塞拉尼斯公司、Disc Medicine、Editas Medicine
Reuters · 11-05
美国研究综述-塞拉尼斯公司、Disc Medicine、Editas Medicine
美国研究综述-信诺、万豪、拉尔夫-劳伦
Reuters · 11-05
美国研究综述-信诺、万豪、拉尔夫-劳伦
美国研究综述-信诺、万豪、拉尔夫-劳伦
Reuters · 11-05
美国研究综述-信诺、万豪、拉尔夫-劳伦
更新版 2-医疗保健行业首次公开募股升温,上游生物估值 11 亿美元,首次公开募股表现亮眼
路透中文 · 10-12
更新版 2-医疗保健行业首次公开募股升温,上游生物估值 11 亿美元,首次公开募股表现亮眼
美股异动 | 生物制药公司Camp4 Therapeutics(CAMP.US)登陆纳斯达克 开盘涨超1%
智通财经 · 10-12
美股异动 | 生物制药公司Camp4 Therapeutics(CAMP.US)登陆纳斯达克 开盘涨超1%
金十数据整理:每日美股市场要闻速递(10月7日 周一)
美港电讯 · 10-07
金十数据整理:每日美股市场要闻速递(10月7日 周一)
CAMP4 Therapeutics(CAMP.US)宣布IPO计划 目标估值达2.83亿美元
智通财经 · 10-07
CAMP4 Therapeutics(CAMP.US)宣布IPO计划 目标估值达2.83亿美元
加载更多
公司概况
公司名称:
Camp4 Therapeutics Corp.
所属市场:
NASDAQ
上市日期:
--
主营业务:
CAMP4 Therapeutics Corporation最初于2015年在特拉华州注册成立,并于2016年开始运营。他们是一家临床阶段的生物制药公司,率先发现和开发了基于RNA的调节疗法,旨在上调基因表达和恢复健康的蛋白质水平,以治疗各种遗传疾病。调节性RNA或regRNAs通过促进基因激活和抑制,在每个蛋白质编码基因的调节中起着核心作用。他们的方法旨在通过利用regRNAs的力量来扩增信使RNA或mRNA的表达,regRNAs与转录因子形成局部复合物并调节基因表达。他们专有的RNA驱动平台或RAP平台使他们能够快速系统地鉴定和表征控制每个表达基因的活性调控元件以及控制蛋白质编码基因的数万个可药物增强剂和启动子regRNA序列。
发行价格:
--
{"stockData":{"symbol":"CAMP","market":"US","secType":"STK","nameCN":"Camp4 Therapeutics Corp.","latestPrice":5.2,"timestamp":1734728399999,"preClose":5.34,"halted":0,"volume":984317,"hourTrading":{"tag":"盘后","latestPrice":5.2,"preClose":5.2,"latestTime":"16:20 EST","volume":88623,"amount":460840.12,"timestamp":1734729600141},"delay":0,"floatShares":6820000,"shares":20161073,"eps":-106.22736,"marketStatus":"休市中","marketStatusCode":7,"change":-0.14,"latestTime":"12-20 15:59:59 EST","open":5.525,"high":6.3,"low":4.66,"amount":5157073.983397,"amplitude":0.307116,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-106.22736,"exchange":"NASDAQ","tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1734944400000},"adr":0,"listingDate":1728619200000,"adjPreClose":5.34,"adrRate":0,"preHourTrading":{"tag":"盘前","latestPrice":5.82,"preClose":5.34,"latestTime":"08:59 EST","volume":155,"amount":902.1,"timestamp":1734703159397},"postHourTrading":{"tag":"盘后","latestPrice":5.2,"preClose":5.2,"latestTime":"16:20 EST","volume":88623,"amount":460840.12,"timestamp":1734729600141},"volumeRatio":8.156084019032011,"impliedVol":2.9143,"impliedVolPercentile":0.9667},"requestUrl":"/m/hq/s/CAMP","defaultTab":"news","newsList":[{"id":"2486705257","title":"单月超6亿美元,医药企业IPO规模重返疫情前水平","url":"https://stock-news.laohu8.com/highlight/detail?id=2486705257","media":"财通社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486705257?lang=zh_cn&edition=full","pubTime":"2024-11-25 17:34","pubTimestamp":1732527240,"startTime":"0","endTime":"0","summary":"今年以来,生物医药领域已经有30家公司IPO上市,累计融资规模超40.49亿美元,其中不乏CG Oncology、Kyverna Therapeutics等IPO规模超3亿美元的公司。在多肽类PTH1R激动剂领域,阿斯利康以总价18亿美元收购AmolytPharma,获得了处于临床3期的PTH1R激动剂eneboparatide,目前该疗法已经获得了FDA快速通道认定,另一家药企AscendisPharma的Yorvipath获得FDA批准上市,用于治疗成人慢性甲状旁腺功能减退。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2024-11-25/doc-incxhqmk8147031.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4561","NQmain","ASO","BK4020","BK4200","BK4599","BK4139","BK4539","OMGA","GLYC","MNQmain","BK4007","QID","TQQQ","TSLP","APGE",".IXIC","BK4082","QLD","CAMP","GPCR","BDMD","SYRS","AVTE","PSQ","UPB","SQQQ","SEPN"],"gpt_icon":1},{"id":"2486792160","title":"Camp4 Therapeutics Corporation2024财年第三财季实现净利润-13.48百万美元,同比减少15.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=2486792160","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486792160?lang=zh_cn&edition=full","pubTime":"2024-11-25 00:00","pubTimestamp":1732464021,"startTime":"0","endTime":"0","summary":"11月25日,Camp4 Therapeutics Corporation公布财报,公告显示公司2024财年第三财季净利润为-13.48百万美元,同比减少15.21%;其中营业收入为0.00美元,每股基本收益为-0.67美元。从资产负债表来看,Camp4 Therapeutics Corporation总负债18.19百万美元,其中短期债务3.28百万美元,资产负债比为1.18,流动比率为0.47。机构评级:截至2024年11月25日,当前有4家机构对Camp4 Therapeutics Corporation目标价做出预测,其中目标均价为21.36美元,其中最低目标价为17.00美元,最高目标价为27.43美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241125000039a2522baf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241125000039a2522baf&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CAMP","LENZ"],"gpt_icon":0},{"id":"2481508022","title":"美国研究综述-塞拉尼斯公司、Disc Medicine、Editas Medicine","url":"https://stock-news.laohu8.com/highlight/detail?id=2481508022","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481508022?lang=zh_cn&edition=full","pubTime":"2024-11-05 20:32","pubTimestamp":1730809940,"startTime":"0","endTime":"0","summary":" 路透11月5日 - 华尔街证券分析师周二调整了对塞拉尼斯公司、Disc Medicine 和 Editas Medicine 等几家美国上市公司的评级和目标价。* Disc Medicine Inc :雷蒙德-詹姆斯将其评级从 \"跑赢大盘 \"上调至 \"强力买入\"。* Editas Medicine Inc :雷蒙德-詹姆斯将其评级从 \"跑赢大市 \"下调至 \"跑赢大市\"。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMG","CHH","LNG","AIG","CW","CC","AFL","BWIN","EGHT","LU2087625088.SGD","BCRX","CRUS","ATUS","CNC","BK4109","HIMS","BKNG","BK4178","CAMP","CBT","ARES","ADVM","CMS","CAR","CHE","BFAM","LU1496350502.SGD","LU0289739699.SGD","CNP","CRGY","CE","CEG","ARHS","DG","LU2065169927.USD","IE00BKVL7J92.USD","LU1699723380.USD","IRON","BOWL","CSTL","CI","AN","CDNA","CBLL","CRBG","IE00BVYPNW00.USD","BK4208","BMRN","AWI","ABG"],"gpt_icon":1},{"id":"2481541559","title":"美国研究综述-信诺、万豪、拉尔夫-劳伦","url":"https://stock-news.laohu8.com/highlight/detail?id=2481541559","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481541559?lang=zh_cn&edition=full","pubTime":"2024-11-05 15:04","pubTimestamp":1730790257,"startTime":"0","endTime":"0","summary":" 路透11月5日 - 华尔街证券分析师周二调整了对几家美国上市公司的评级和目标价,其中包括 Cigna、万豪和 Ralph Lauren。要闻 * Cigna :Piper Sandler将目标价从392美元上调至394美元 * 万豪 :杰富瑞将目标价从 225 美元上调至 251 美元 * Ralph Lauren Corp :TD Cowen 将目标价从 208 美元上调至 251 美元 * Vertex Pharmaceuticals Inc :丰业银行将目标价从480美元上调至486美元 * Wynn Resorts Ltd :摩根大通将目标价从101美元上调至113美元 以下是路透周二报导的美国公司研究报告摘要。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMG","HIMS","LU1489326972.SGD","BEN","LSCC","CI","FRPT","CSTL","EDIT","FOXA","INSP","SHAK","ILMN","RZLT","BMRN","IE00BZ1G4Q59.USD","MDGL","BWIN","NMRA","MAR","KROS","EGHT","LU1244550221.USD","RL","IRON","FIS","SM","PTGX","ARES","ST","LU0949170772.SGD","SLAB","LU0149725797.USD","CMS","BK4106","EVER","OMI","LU1363072403.SGD","LU0971096721.USD","GKOS","CAMP","LU","LU0320765489.SGD","LU0266512127.USD","ATUS","AWI","NYT"],"gpt_icon":1},{"id":"2481415545","title":"美国研究综述-信诺、万豪、拉尔夫-劳伦","url":"https://stock-news.laohu8.com/highlight/detail?id=2481415545","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481415545?lang=zh_cn&edition=full","pubTime":"2024-11-05 15:04","pubTimestamp":1730790257,"startTime":"0","endTime":"0","summary":" 路透11月5日 - 华尔街证券分析师周二调整了对几家美国上市公司的评级和目标价,其中包括 Cigna、万豪和 Ralph Lauren。要闻 * Cigna :Piper Sandler将目标价从392美元上调至394美元 * 万豪 :杰富瑞将目标价从 225 美元上调至 251 美元 * Ralph Lauren Corp :TD Cowen 将目标价从 208 美元上调至 251 美元 * Vertex Pharmaceuticals Inc :丰业银行将目标价从480美元上调至486美元 * Wynn Resorts Ltd :摩根大通将目标价从101美元上调至113美元 以下是路透周二报道的美国公司研究报告摘要。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AWI","LU1363072403.SGD","NMRA","MDGL","CAMP","EVER","ARES","LU0266512127.USD","CMS","LSCC","ATUS","CI","BEN","SHAK","FIS","OMI","IE00BZ1G4Q59.USD","LU0971096721.USD","RZLT","ST","AMG","KROS","CSTL","GKOS","LU0949170772.SGD","PTGX","SLAB","INSP","ILMN","FOXA","MAR","BWIN","NYT","SM","LU","FRPT","LU0149725797.USD","BMRN","LU1244550221.USD","BK4106","LU0320765489.SGD","EGHT","IRON","LU1489326972.SGD","EDIT","RL"],"gpt_icon":1},{"id":"2474107260","title":"更新版 2-医疗保健行业首次公开募股升温,上游生物估值 11 亿美元,首次公开募股表现亮眼","url":"https://stock-news.laohu8.com/highlight/detail?id=2474107260","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2474107260?lang=zh_cn&edition=full","pubTime":"2024-10-12 00:49","pubTimestamp":1728665391,"startTime":"0","endTime":"0","summary":"更新版 2-医疗保健行业首次公开募股升温,上游生物估值 11 亿美元,首次公开募股表现亮眼上游股票较首次公开募股价格上涨 26.5%药物开发商开盘估值 11 亿美元医疗保健行业引领 2024 年美国 IPO 市场 第 8、11、12 段通篇添加了背景资料和分析师评论,图文并茂Arasu Kannagi Basil路透10月11日 - 上游生物UPB.O周五在纳斯达克首次公开上市,开盘价比首次公开发行价高出26.5%,这家药品开发商的估值达到10.5亿美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241011:nL4S3LN1F2:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CAMP","BK4020"],"gpt_icon":0},{"id":"2474546014","title":"美股异动 | 生物制药公司Camp4 Therapeutics(CAMP.US)登陆纳斯达克 开盘涨超1%","url":"https://stock-news.laohu8.com/highlight/detail?id=2474546014","media":"智通财经","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2474546014?lang=zh_cn&edition=full","pubTime":"2024-10-12 00:15","pubTimestamp":1728663321,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,周五,由医疗巨头Kaiser Permanente支持的生物制药公司Camp4 Therapeutics(CAMP.US)登陆纳斯达克,开盘涨超1%,报11.16美元,IPO价格为11美元。这家位于马萨诸塞州剑桥市的公司正在开发治疗多种遗传疾病的疗法。其主要候选产品CMP-CPS-001用于治疗最常见的尿素循环疾病,目前正在早期临床试验中进行评估。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1192996.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["SQQQ","BK1147","MNQmain","BK4139","NQmain","LENZ","PSQ","BK4020","BK4007","TQQQ","QID","QLD","03086","159632",".IXIC","CAMP","ARTL"],"gpt_icon":0},{"id":"2473170920","title":"金十数据整理:每日美股市场要闻速递(10月7日 周一)","url":"https://stock-news.laohu8.com/highlight/detail?id=2473170920","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2473170920?lang=zh_cn&edition=full","pubTime":"2024-10-07 20:56","pubTimestamp":1728305780,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":[".SPX","RIO.UK","SH","LENZ","BK4527","RDS.A","FSR","US5Y.BOND","US3Y.BOND","SDS","01093","US10Y.BOND","RDSA.UK","BK4504","AAPL","OEF","BK4170","SEC.AU","CAMP","US12M.BOND","RDS.B","OEX","HK0000934320.USD","US912797GW17.BOND","US30Y.BOND","BK4144","ALTM","SHEL","FSRNQ","US6M.BOND","HK0000306685.HKD","LU1829250122.USD","US2Y.BOND","US912797HE00.BOND","LU1152091168.USD","SPY","SPXU","IE0008368742.USD","SSO","SG9999001143.SGD","BK4505","AZN","RIO","US7Y.BOND","IVV","LU0345781412.USD","BK4168","PLS.AU","UPRO","ESmain"],"gpt_icon":0},{"id":"2473174405","title":"CAMP4 Therapeutics(CAMP.US)宣布IPO计划 目标估值达2.83亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2473174405","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2473174405?lang=zh_cn&edition=full","pubTime":"2024-10-07 20:06","pubTimestamp":1728302809,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,由医疗巨头Kaiser Permanente支持的生物制药公司CAMP4 Therapeutics周一表示,将在美国首次公开募股中寻求至多2.83亿美元的目标估值。CAMP4计划发行500万股股票,每股定价在14美元至16美元之间,筹资至多8,000万美元。其主要候选产品CMP-CPS-001用于治疗最常见的尿素循环疾病,目前正在早期临床试验中进行评估。CAMP4由曾在渤健和赛诺菲安万特工作的Josh mandelbrehm领导。该公司将在纳斯达克上市,代码为“CAMP”。摩根大通、Leerink Partners、Piper Sandler和William Blair是此次IPO的承销商。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1190655.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4139","LENZ","BK4020","CAMP"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.camp4tx.com","stockEarnings":[{"period":"1week","weight":-0.3185},{"period":"1month","weight":-0.0244},{"period":"3month","weight":-0.5273},{"period":"ytd","weight":-0.5273}],"compareEarnings":[{"period":"1week","weight":-0.0221},{"period":"1month","weight":0.0006},{"period":"3month","weight":0.0397},{"period":"6month","weight":0.0851},{"period":"1year","weight":0.2499},{"period":"ytd","weight":0.243}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"CAMP4 Therapeutics Corporation最初于2015年在特拉华州注册成立,并于2016年开始运营。他们是一家临床阶段的生物制药公司,率先发现和开发了基于RNA的调节疗法,旨在上调基因表达和恢复健康的蛋白质水平,以治疗各种遗传疾病。调节性RNA或regRNAs通过促进基因激活和抑制,在每个蛋白质编码基因的调节中起着核心作用。他们的方法旨在通过利用regRNAs的力量来扩增信使RNA或mRNA的表达,regRNAs与转录因子形成局部复合物并调节基因表达。他们专有的RNA驱动平台或RAP平台使他们能够快速系统地鉴定和表征控制每个表达基因的活性调控元件以及控制蛋白质编码基因的数万个可药物增强剂和启动子regRNA序列。","yearOnYearQuotes":[{"month":1,"riseRate":0.682927,"avgChangeRate":0.082077},{"month":2,"riseRate":0.463415,"avgChangeRate":-0.002283},{"month":3,"riseRate":0.414634,"avgChangeRate":-0.012666},{"month":4,"riseRate":0.475,"avgChangeRate":0.03701},{"month":5,"riseRate":0.55,"avgChangeRate":0.007695},{"month":6,"riseRate":0.390244,"avgChangeRate":-0.040171},{"month":7,"riseRate":0.35,"avgChangeRate":0.010243},{"month":8,"riseRate":0.55,"avgChangeRate":0.035717},{"month":9,"riseRate":0.512195,"avgChangeRate":0.024414},{"month":10,"riseRate":0.45,"avgChangeRate":0.026175},{"month":11,"riseRate":0.5,"avgChangeRate":0.04865},{"month":12,"riseRate":0.375,"avgChangeRate":-0.039343}],"exchange":"NASDAQ","name":"Camp4 Therapeutics Corp.","nameEN":"Camp4 Therapeutics Corp."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Camp4 Therapeutics Corp.(CAMP)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Camp4 Therapeutics Corp.(CAMP)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Camp4 Therapeutics Corp.,CAMP,Camp4 Therapeutics Corp.股票,Camp4 Therapeutics Corp.股票老虎,Camp4 Therapeutics Corp.股票老虎国际,Camp4 Therapeutics Corp.行情,Camp4 Therapeutics Corp.股票行情,Camp4 Therapeutics Corp.股价,Camp4 Therapeutics Corp.股市,Camp4 Therapeutics Corp.股票价格,Camp4 Therapeutics Corp.股票交易,Camp4 Therapeutics Corp.股票购买,Camp4 Therapeutics Corp.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Camp4 Therapeutics Corp.(CAMP)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Camp4 Therapeutics Corp.(CAMP)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}